Spring Sale: Up to 50% OFF · Ends Tonight

Does Zepbound Cause Hair Loss? Tirzepatide Side Effects Explained

Updated 2026-04-17 9 min read By Provant Labs Research Team

Yes, Zepbound causes hair loss. The FDA Zepbound label lists alopecia in 7.1% of women versus 0.5% of men in the pooled obesity trials. Across the SURMOUNT clinical trial program, alopecia rates with tirzepatide ran 4.9-7.0% versus 0.9-1.4% for placebo. This is among the most sex-specific drug side effects in any recently approved medication's prescribing information.

Here's everything the data shows.

Zepbound and Mounjaro: Same Drug, Different Names

Before going into the data, one clarification that trips up a lot of patients: Zepbound and Mounjaro are the same molecule, tirzepatide. Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes and as Zepbound for obesity management.

The obesity trials (Zepbound indication) produce greater weight loss, so the hair loss data is more prominent in Zepbound's prescribing information. But if you're on Mounjaro and losing significant weight, the Zepbound data is your most relevant reference.

For a full breakdown of the Mounjaro-specific framing, see the Mounjaro hair loss article.

The FDA Zepbound Label: What It Actually Reports

The Zepbound FDA prescribing information (tirzepatide for chronic weight management, approved November 2023) includes detailed alopecia data from pooled Studies 1 and 2.

Overall rates:

Sex-stratified data:

The 7.1% women's figure and 0.5% men's figure are the clearest sex-stratified hair loss numbers in any GLP-1 medication label. No other approved GLP-1 drug's prescribing information breaks it down this explicitly.

And the label notes: no patient discontinued Zepbound because of alopecia in these trials. Real and documented, but not at a severity level that drove treatment stoppage in the formal data.

The SURMOUNT Trial Data

The SURMOUNT Phase 3 program is the most complete clinical dataset for tirzepatide hair loss.

SURMOUNT-1 (Jastreboff et al., NEJM 2022, Phase 3, n=2,539, 72 weeks):

Dose Alopecia
5mg 5.1%
10mg 5.3%
15mg 4.9%
Placebo 0.9%

Weight loss achieved: -15% to -20.9% body weight vs -3.1% placebo. The lack of dose escalation in the hair loss rate (5.1% vs 5.3% vs 4.9%) tells you the relevant variable isn't the drug dose. It's the weight loss.

SURMOUNT-3 (Wadden et al., Nature Medicine 2023, Phase 3, n=579, 72 weeks):

The 7.0% in SURMOUNT-3 is the highest alopecia rate published from any tirzepatide trial. Participants entered this study having already lost weight through an intensive behavioral program, making their total cumulative weight loss larger. That context explains the elevated rate.

Pooled SURMOUNT meta-analysis (PMC11576767):

Nearly 6x the odds of alopecia compared to placebo. That's a strong pharmacological signal.

The Pharmacovigilance Data: Godfrey et al. 2025

Controlled trials capture outcomes in structured populations with scheduled visits. Pharmacovigilance systems capture what happens in the broader real world of clinical practice.

Godfrey et al. 2025 (Journal of the European Academy of Venereology and Dermatology) analyzed FDA Adverse Event Reporting System (FAERS) data from 2022-2023. This was the first systematic pharmacovigilance analysis specifically examining alopecia signals for GLP-1 medications.

Results:

An ROR above 1.0 means the drug-event combination is reported at higher-than-expected frequency given the full FAERS database. Tirzepatide's 1.73 exceeds this threshold. The consumer-driven (84%) nature of reports reflects a side effect patients identify and report directly.

The semaglutide ROR (2.46) is higher than tirzepatide's (1.73). This may reflect semaglutide's longer market presence generating more total reports, or a genuine pharmacological difference. Without a direct head-to-head trial, that comparison is directional, not definitive.

Why Zepbound Hair Loss Is Concentrated in Women

The 14-fold sex differential (7.1% women vs 0.5% men) demands an explanation. Three converging mechanisms produce it.

Estrogen pathways. Tirzepatide's effects on GIP and GLP-1 receptors, combined with rapid weight loss, reduce LH (luteinizing hormone) and FSH (follicle-stimulating hormone). Lower LH/FSH means less estrogen production. Women's hair follicles are highly sensitive to estrogen shifts. This is why new mothers experience postpartum shedding (estrogen drops sharply after delivery), why perimenopause is a major hair loss trigger, and why rapid-weight-loss drugs that affect gonadotropin levels preferentially affect women.

Hair follicle biology. The decision of whether a follicle stays in the growth phase (anagen) or shifts to rest (telogen) is partly governed by systemic hormonal environment. Caloric restriction signals metabolic stress. Hormonal changes reinforce that signal. Women's follicles respond to this combination more readily than men's.

Demographic concentration. The highest-use group for GLP-1 medications is women aged 50-64, approximately 1 in 5 of whom are on these medications. Many are in or near perimenopause, where hormonal vulnerability to hair loss already exists. The drug's effect layers onto an existing hormonal susceptibility.

But strip away the demographics: the biology alone produces a 14x differential. That's not a coincidence of who's in the trial. It's a mechanism.

What Telogen Effluvium Is (and Why Zepbound Triggers It)

Telogen effluvium is the clinical name for the shedding pattern associated with Zepbound use. It's not hair loss in the sense of follicle destruction. It's a forced synchronization of the hair cycle.

Normal hair grows in three phases: anagen (active growth, 2-8 years, 85-95% of follicles), catagen (brief transition, less than 1% of follicles), and telogen (rest, 2-3 months, 4-14% of follicles). Every day, telogen follicles release their club hairs and new anagen hairs grow in behind them. You lose 100-150 hairs on a normal day. You don't notice it because it's staggered.

During rapid weight loss, metabolic stress signals push a large portion of follicles from anagen to telogen simultaneously. Two to four months later, they all release at once. That's the sudden increase in shedding, the clumps in the shower, the hair on the pillow, the noticeable thinning.

The Annals of Dermatology 2024 retrospective cohort study (n=140, 78.6% women) quantified the TE timeline specifically for weight-loss contexts: average onset 1.12 months after weight loss begins, average recovery 4.83 months after the trigger stabilizes, without any treatment intervention.

But here's what makes GLP-1 TE different from the typical pattern: the trigger is continuous. As long as you're actively losing weight on Zepbound, the signal doesn't stop. Women on Zepbound often describe months of persistent shedding rather than a single acute wave. That's mechanistically consistent with a drug that produces sustained caloric deficit.

TriNetX Cohort: Real-World Evidence at Scale

Beyond trials and pharmacovigilance, the TriNetX multicenter cohort study (2025) used data from 67 healthcare organizations to match 547,993 GLP-1 users against 547,993 non-users with similar baseline characteristics.

At 12 months:

The androgenic alopecia finding (aOR 1.64) is the one that deserves attention. Androgenic alopecia is genetic, progressive, and caused by DHT sensitivity in predisposed follicles. The elevated odds in GLP-1 users suggests the medication may unmask or accelerate an underlying hair loss pattern in some patients. Unlike TE, androgenic alopecia doesn't fully reverse when weight stabilizes.

If your shedding on Zepbound is diffuse (all-over), that's consistent with TE. If it's concentrated at the temples, crown, or in a specific pattern, a dermatology evaluation is worth doing to distinguish the two.

How to Address Zepbound Hair Loss Without Stopping the Medication

Hair loss was cited as one of the top reasons patients stop GLP-1 medications. That's a costly trade-off given the metabolic benefits of these drugs. The evidence supports approaches that work alongside continued treatment.

Protein intake. Hair follicles are primarily protein. Zepbound suppresses appetite, and many patients end up well below 60g of protein per day. Hitting 60-100g daily is protective. It's harder than it sounds on a drug that eliminates hunger, but it's measurable and addressable.

Iron and ferritin. Ferritin below 30 ng/mL is strongly associated with telogen effluvium, particularly in women. A blood panel identifying low ferritin followed by supplementation addresses one of the most correctable contributors to prolonged shedding.

Topical scalp support. The follicle environment responds to topical interventions with clinical evidence behind them. Rosemary extract matched minoxidil 2% in a head-to-head RCT (Panahi et al., SKINmed 2015, n=100), and Patel et al. 2025 (Cureus, n=90) found rosemary-based treatment produced 57.73% improvement in hair growth rate. Saw palmetto reduced shedding 22.19% and improved density 7.61% in a topical RCT (Sudeep et al., CCID 2023, n=80). The PD-5 Complex combines these with bioactive peptides in a topical formula designed for GLP-1-related shedding.

Timeline awareness. The hair you're losing today reflects follicles that entered telogen 2-4 months ago. Interventions you start now affect the follicles currently in anagen, which are the ones visible 3-6 months from now. Starting earlier produces better outcomes than waiting for the shedding to stop.

The GLP-1 hair loss guide covers the full evidence base for all interventions worth considering.

FAQ

Does Zepbound cause hair loss in everyone?

No. The trial data shows 4.9-7.0% in treatment arms versus 0.9-1.4% in placebo. Most Zepbound patients don't formally report alopecia. But 7.1% of women in the combined obesity trials did. Real-world rates may be higher than trial rates, given that trial adverse event reporting typically undercounts subjective symptoms like hair thinning.

When does Zepbound hair loss start?

The typical telogen effluvium pattern starts 2-4 months after the metabolic trigger begins. The Annals of Dermatology 2024 retrospective cohort (n=140) found average onset 1.12 months after weight loss starts, but individual timing varies. Some women notice it at 6-8 weeks, others not until month 4 or 5.

Is Zepbound hair loss permanent?

For most women, no. Telogen effluvium from weight loss is reversible. The follicles haven't been destroyed. But the TriNetX cohort (n=547,993) found elevated odds of androgenic alopecia (aOR 1.64) in GLP-1 users, suggesting some patients may have an underlying genetic hair loss pattern that the medication uncovers or accelerates. If hair loss doesn't recover after weight stabilizes, a dermatology evaluation can distinguish between the two.

Is Zepbound hair loss worse than Wegovy?

The Zepbound label's 7.1% women's figure is higher than the Wegovy injectable label's 3% overall figure. But the OASIS 1 trial for oral semaglutide found 6.9%, and SURMOUNT-3 found 7.0% for tirzepatide. Both drugs produce comparable weight loss. The available data doesn't clearly rank one above the other. Both are associated with a significant sex-specific signal in women.

Should I stop Zepbound because of hair loss?

That's a conversation for your prescriber, not a decision to make alone. The metabolic benefits of Zepbound for weight management and cardiovascular risk are well-established. Reversible temporary hair loss versus long-term metabolic control is a trade-off that depends on individual circumstances, severity of shedding, and alternative options. Most women find the hair loss manageable when they understand the mechanism and address contributing factors like protein intake, iron status, and scalp support.

Why does Zepbound cause more hair loss in women than men?

The Zepbound label reports 7.1% in women versus 0.5% in men on the same drug at the same doses, a 14-fold difference. The primary mechanism is hormonal: GLP-1 and GIP receptor activation combined with rapid weight loss reduces LH and FSH, which lowers estrogen production. Women's hair follicles are highly sensitive to estrogen changes. Men don't experience the same estrogen-mediated signaling in follicles. The biology of the sex difference is well-established and consistent with the postpartum and perimenopause hair loss patterns that affect women but not men.

Ready to support your hair during your GLP-1 journey?

See the PD-5 Complex